An act to maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes
PL 115-180 (S.292), enacted 06/05/2018

132 STAT. 1382 
PUBLIC LAW 115–180—JUNE 5, 2018 
Public Law 115–180 
115th Congress 
An Act 
To maximize discovery, and accelerate development and availability, of promising 
childhood cancer treatments, and for other purposes. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the ‘‘Childhood 
Cancer Survivorship, Treatment, Access, and Research Act of 2018’’ 
or the ‘‘Childhood Cancer STAR Act’’. 
(b) TABLE OF CONTENTS.—The table of contents for this Act 
is as follows: 
Sec. 1. Short title; table of contents. 
TITLE I—MAXIMIZING RESEARCH THROUGH DISCOVERY 
Subtitle A—Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act 
Sec. 101. Children’s cancer biorepositories and biospecimen research. 
Sec. 102. Improving Childhood Cancer Surveillance. 
Subtitle B—Pediatric Expertise at NIH 
Sec. 111. Inclusion of at least one pediatric oncologist on the National Cancer Advi-
sory Board. 
Sec. 112. Sense of Congress regarding pediatric expertise at the National Cancer 
Institute. 
Subtitle C—NIH Reporting on Childhood Cancer Activities 
Sec. 121. Reporting on childhood cancer research projects. 
TITLE II—MAXIMIZING DELIVERY: CARE, QUALITY OF LIFE, 
SURVIVORSHIP, AND CAREGIVER SUPPORT 
Sec. 201. Cancer survivorship programs. 
Sec. 202. Grants to improve care for pediatric cancer survivors. 
Sec. 203. Best practices for long-term follow-up services for pediatric cancer sur-
vivors. 
Sec. 204. Technical amendment. 
Childhood 
Cancer 
Survivorship, 
Treatment, 
Access, and 
Research Act 
of 2018. 
42 USC 201 note. 
June 5, 2018 
[S. 292] 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00157
Fmt 6580
Sfmt 6582
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1383 
PUBLIC LAW 115–180—JUNE 5, 2018 
TITLE I—MAXIMIZING RESEARCH 
THROUGH DISCOVERY 
Subtitle A—Caroline Pryce Walker Con-
quer Childhood Cancer Reauthorization 
Act 
SEC. 101. CHILDREN’S CANCER BIOREPOSITORIES AND BIOSPECIMEN 
RESEARCH. 
Section 417E of the Public Health Service Act (42 U.S.C. 285a– 
11) is amended— 
(1) in the section heading, by striking ‘‘RESEARCH AND 
AWARENESS’’ and inserting ‘‘RESEARCH, AWARENESS, AND 
SURVIVORSHIP’’; 
(2) by striking subsection (a) and inserting the following: 
‘‘(a) CHILDREN’S CANCER BIOREPOSITORIES.— 
‘‘(1) AWARD.—The Secretary, acting through the Director 
of NIH, may make awards to an entity or entities described 
in paragraph (4) to build upon existing research efforts to 
collect biospecimens and clinical and demographic information 
of children, adolescents, and young adults with selected cancer 
subtypes (and their recurrences) for which current treatments 
are least effective, in order to achieve a better understanding 
of the causes of such cancer subtypes (and their recurrences), 
and the effects and outcomes of treatments for such cancers. 
‘‘(2) USE OF FUNDS.—Amounts received under an award 
under paragraph (1) may be used to carry out the following: 
‘‘(A) Collect and store high-quality, donated biospeci-
mens and associated clinical and demographic information 
on children, adolescents, and young adults diagnosed with 
cancer in the United States, focusing on children, adoles-
cents, and young adults with cancer enrolled in clinical 
trials for whom current treatments are least effective. 
Activities under this subparagraph may include storage 
of biospecimens and associated clinical and demographic 
data at existing biorepositories supported by the National 
Cancer Institute. 
‘‘(B) Maintain an interoperable, secure, and searchable 
database on stored biospecimens and associated clinical 
and demographic data from children, adolescents, and 
young adults with cancer for the purposes of research by 
scientists and qualified health care professionals. 
‘‘(C) Establish and implement procedures for evalu-
ating applications for access to such biospecimens and clin-
ical and demographic data from researchers and other 
qualified health care professionals. 
‘‘(D) Provide access to biospecimens and clinical and 
demographic data from children, adolescents, and young 
adults with cancer to researchers and qualified health care 
professionals for peer-reviewed research— 
‘‘(i) consistent with the procedures established 
pursuant to subparagraph (C); 
‘‘(ii) only to the extent permitted by applicable 
Federal and State law; and 
Procedures. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00158
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1384 
PUBLIC LAW 115–180—JUNE 5, 2018 
‘‘(iii) in a manner that protects personal privacy 
to the extent required by applicable Federal and State 
privacy law, at minimum. 
‘‘(3) NO
REQUIREMENT.—No child, adolescent, or young 
adult with cancer shall be required under this subsection to 
contribute a specimen to a biorepository or share clinical or 
demographic data. 
‘‘(4) APPLICATION; CONSIDERATIONS.— 
‘‘(A) APPLICATION.—To be eligible to receive an award 
under paragraph (1) an entity shall submit an application 
to the Secretary at such a time, in such manner, and 
containing such information as the Secretary may reason-
ably require. 
‘‘(B) CONSIDERATIONS.—In evaluating applications sub-
mitted under subparagraph (A), the Secretary shall con-
sider the existing infrastructure of the entity that would 
allow for the timely capture of biospecimens and related 
clinical and demographic information for children, adoles-
cents, and young adults with cancer for whom current 
treatments are least effective. 
‘‘(5) PRIVACY PROTECTIONS AND INFORMED CONSENT.— 
‘‘(A) IN GENERAL.—The Secretary may not make an 
award under paragraph (1) to an entity unless the Sec-
retary ensures that such entity— 
‘‘(i) collects biospecimens and associated clinical 
and demographic information only from participants 
who have given their informed consent in accordance 
with Federal and State law; and 
‘‘(ii) protects personal privacy to the extent 
required by applicable Federal and State law, at min-
imum. 
‘‘(B) INFORMED CONSENT.—The Secretary shall ensure 
biospecimens and associated clinical and demographic 
information are collected with informed consent, as 
described in subparagraph (A)(i). 
‘‘(6) GUIDELINES
AND
OVERSIGHT.—The Secretary shall 
develop and disseminate appropriate guidelines for the develop-
ment and maintenance of the biorepositories supported under 
this subsection, including appropriate oversight, to facilitate 
further research on select cancer subtypes (and their 
recurrences) in children, adolescents, and young adults with 
such cancers (and their recurrences). 
‘‘(7) COORDINATION.—To encourage the greatest possible 
efficiency and effectiveness of federally supported efforts with 
respect to the activities described in this subsection, the Sec-
retary shall ensure the appropriate coordination of programs 
supported under this section with existing federally supported 
cancer registry programs and the activities under section 399E– 
1, as appropriate. 
‘‘(8) SUPPLEMENT NOT SUPPLANT.—Funds provided under 
this subsection shall be used to supplement, and not supplant, 
Federal and non-Federal funds available for carrying out the 
activities described in this subsection. 
‘‘(9) REPORT.—Not later than 4 years after the date of 
enactment of the Childhood Cancer Survivorship, Treatment, 
Access, and Research Act of 2018, the Secretary shall submit 
to Congress a report on— 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00159
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1385 
PUBLIC LAW 115–180—JUNE 5, 2018 
‘‘(A) the number of biospecimens and corresponding 
clinical demographic data collected through the biospeci-
men research efforts supported under paragraph (1); 
‘‘(B) the number of biospecimens and corresponding 
clinical demographic data requested for use by researchers; 
‘‘(C) barriers to the collection of biospecimens and cor-
responding clinical demographic data; 
‘‘(D) barriers experienced by researchers or health care 
professionals in accessing the biospecimens and cor-
responding clinical demographic data necessary for use in 
research; and 
‘‘(E) recommendations with respect to improving the 
biospecimen and biorepository research efforts under this 
subsection. 
‘‘(10) DEFINITIONS.—For purposes of this subsection: 
‘‘(A) AWARD.—The term ‘award’ includes a grant, con-
tract, or cooperative agreement determined by the Sec-
retary. 
‘‘(B) BIOSPECIMEN.—The term ‘biospecimen’ includes— 
‘‘(i) solid tumor tissue or bone marrow; 
‘‘(ii) normal or control tissue; 
‘‘(iii) blood and plasma; 
‘‘(iv) DNA and RNA extractions; 
‘‘(v) familial DNA; and 
‘‘(vi) any other sample relevant to cancer research, 
as required by the Secretary. 
‘‘(C) CLINICAL AND DEMOGRAPHIC INFORMATION.—The 
term ‘clinical and demographic information’ includes— 
‘‘(i) date of diagnosis; 
‘‘(ii) age at diagnosis; 
‘‘(iii) the patient’s sex, race, ethnicity, and environ-
mental exposures; 
‘‘(iv) extent of disease at enrollment; 
‘‘(v) site of metastases; 
‘‘(vi) location of primary tumor coded; 
‘‘(vii) histologic diagnosis; 
‘‘(viii) tumor marker data when available; 
‘‘(ix) treatment and outcome data; 
‘‘(x) information related to specimen quality; and 
‘‘(xi) any other applicable information required by 
the Secretary.’’; and 
(3) in subsection (c), by striking ‘‘(42 U.S.C. 202 note)’’. 
SEC. 102. IMPROVING CHILDHOOD CANCER SURVEILLANCE. 
(a) IN GENERAL.—Section 399E–1 of the Public Health Service 
Act (42 U.S.C. 280e–3a) is amended— 
(1) in subsection (a)— 
(A) by striking ‘‘shall award a grant’’ and inserting 
‘‘may make awards to State cancer registries’’; and 
(B) by striking ‘‘track the epidemiology of pediatric 
cancer into a comprehensive nationwide registry of actual 
occurrences of pediatric cancer’’ and inserting ‘‘collect 
information to better understand the epidemiology of cancer 
in children, adolescents, and young adults’’; and 
(C) by striking the second sentence and inserting ‘‘Such 
registries may be updated to include each occurrence of 
Recommenda- 
tions. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00160
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1386 
PUBLIC LAW 115–180—JUNE 5, 2018 
such cancers within a period of time designated by the 
Secretary.’’; 
(2) by redesignating subsection (b) as subsection (d); 
(3) by inserting after subsection (a) the following: 
‘‘(b) ACTIVITIES.—The grants described in subsection (a) may 
be used for— 
‘‘(1) identifying, recruiting, and training potential sources 
for reporting childhood, adolescent, and young adult cancer 
cases; 
‘‘(2) developing practices to ensure early inclusion of child-
hood, adolescent, and young adult cancer cases in State cancer 
registries through the use of electronic reporting; 
‘‘(3) collecting and submitting deidentified data to the Cen-
ters for Disease Control and Prevention for inclusion in a 
national database that includes information on childhood, 
adolescent, and young adult cancers; and 
‘‘(4) improving State cancer registries and the database 
described in paragraph (3), as appropriate, including to support 
the early inclusion of childhood, adolescent, and young adult 
cancer cases. 
‘‘(c) COORDINATION.—To encourage the greatest possible effi-
ciency and effectiveness of federally supported efforts with respect 
to the activities described in this section, the Secretary shall ensure 
the appropriate coordination of programs supported under this sec-
tion with other federally supported cancer registry programs and 
the activities under section 417E(a), as appropriate.’’; and 
(4) in subsection (d), as so redesignated, by striking ‘‘reg-
istry established pursuant to subsection (a)’’ and inserting 
‘‘activities described in this section’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—Section 417E(d) of the 
Public Health Service Act (42 U.S.C. 285a–11(d)) is amended— 
(1) by striking ‘‘2009 through 2013’’ and inserting ‘‘2019 
through 2023’’; and 
(2) by striking the second sentence. 
Subtitle B—Pediatric Expertise at NIH 
SEC. 111. INCLUSION OF AT LEAST ONE PEDIATRIC ONCOLOGIST ON 
THE NATIONAL CANCER ADVISORY BOARD. 
Clause (iii) of section 406(h)(2)(A) of the Public Health Service 
Act (42 U.S.C. 284a(h)(2)(A)) is amended— 
(1) by striking ‘‘Board not less than five’’ and inserting 
‘‘Board— 
‘‘(I) not less than 5’’; 
(2) by inserting ‘‘and’’ after the semicolon; and 
(3) by adding at the end the following: 
‘‘(II) not less than one member shall be an individual 
knowledgeable in pediatric oncology;’’. 
SEC. 112. SENSE OF CONGRESS REGARDING PEDIATRIC EXPERTISE 
AT THE NATIONAL CANCER INSTITUTE. 
It is the sense of Congress that the Director of the National 
Cancer Institute should ensure that all applicable study sections, 
committees, advisory groups, and panels at the National Cancer 
Institute include one or more qualified pediatric oncologists, as 
appropriate. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00161
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1387 
PUBLIC LAW 115–180—JUNE 5, 2018 
Subtitle C—NIH Reporting on Childhood 
Cancer Activities 
SEC. 121. REPORTING ON CHILDHOOD CANCER RESEARCH PROJECTS. 
The Director of the National Institutes of Health shall ensure 
that childhood cancer research projects conducted or supported by 
the National Institutes of Health are included in appropriate reports 
to Congress, which may include the Pediatric Research Initiative 
report. 
TITLE 
II—MAXIMIZING 
DELIVERY: 
CARE, QUALITY OF LIFE, SURVIVOR-
SHIP, AND CAREGIVER SUPPORT 
SEC. 201. CANCER SURVIVORSHIP PROGRAMS. 
(a) PILOT PROGRAMS TO EXPLORE MODEL SYSTEMS OF CARE 
FOR PEDIATRIC CANCER SURVIVORS.— 
(1) IN
GENERAL.—The Secretary of Health and Human 
Services (referred to in this section as the ‘‘Secretary’’) may 
make awards to eligible entities to establish pilot programs 
to develop, study, or evaluate model systems for monitoring 
and caring for childhood cancer survivors throughout their life-
span, including evaluation of models for transition to adult 
care and care coordination. 
(2) AWARDS.— 
(A) TYPES OF ENTITIES.—In making awards under this 
subsection, the Secretary shall, to the extent practicable, 
include— 
(i) small, medium, and large-sized eligible entities; 
and 
(ii) sites located in different geographic areas, 
including rural and urban areas. 
(B) ELIGIBLE ENTITIES.—In this subsection, the term 
‘‘eligible entity’’ means— 
(i) a medical school; 
(ii) a children’s hospital; 
(iii) a cancer center; 
(iv) a community-based medical facility; or 
(v) any other entity with significant experience 
and expertise in treating survivors of childhood can-
cers. 
(3) USE OF FUNDS.—Funds awarded under this subsection 
may be used— 
(A) to develop, study, or evaluate one or more models 
for monitoring and caring for cancer survivors; and 
(B) in developing, studying, and evaluating such 
models, to give special emphasis to— 
(i) design of models of follow-up care, monitoring, 
and other survivorship programs (including peer sup-
port and mentoring programs); 
(ii) development of models for providing multidisci-
plinary care; 
42 USC 285a–11 
note. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00162
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1388 
PUBLIC LAW 115–180—JUNE 5, 2018 
(iii) dissemination of information to health care 
providers about culturally and linguistically appro-
priate follow-up care for cancer survivors and their 
families, as appropriate and practicable; 
(iv) development of psychosocial and support pro-
grams to improve the quality of life of cancer survivors 
and their families, which may include peer support 
and mentoring programs; 
(v) design of systems for the effective transfer of 
treatment information and care summaries from cancer 
care providers to other health care providers (including 
risk factors and a plan for recommended follow-up 
care); 
(vi) dissemination of the information and programs 
described in clauses (i) through (v) to other health 
care providers (including primary care physicians and 
internists) and to cancer survivors and their families, 
where appropriate and in accordance with Federal and 
State law; and 
(vii) development of initiatives that promote the 
coordination and effective transition of care between 
cancer care providers, primary care physicians, mental 
health professionals, and other health care profes-
sionals, as appropriate, including models that use a 
team-based or multi-disciplinary approach to care. 
(b) WORKFORCE DEVELOPMENT FOR HEALTH CARE PROVIDERS 
ON MEDICAL
AND PSYCHOSOCIAL CARE
FOR CHILDHOOD CANCER 
SURVIVORS.— 
(1) IN GENERAL.—The Secretary shall, not later than 1 
year after the date of enactment of this Act, conduct a review 
of the activities of the Department of Health and Human Serv-
ices related to workforce development for health care providers 
who treat pediatric cancer patients and survivors. Such review 
shall include— 
(A) an assessment of the effectiveness of supportive 
psychosocial care services for pediatric cancer patients and 
survivors, including pediatric cancer survivorship care 
patient navigators and peer support programs; 
(B) identification of existing models relevant to pro-
viding medical and psychosocial services to individuals sur-
viving pediatric cancers, and programs related to training 
for health professionals who provide such services to 
individuals surviving pediatric cancers; and 
(C) recommendations for improving the provision of 
psychosocial care for pediatric cancer survivors and 
patients. 
(2) REPORT.—Not later than 2 years after the date of enact-
ment of this Act, the Secretary shall submit to the Committee 
on Health, Education, Labor, and Pensions of the Senate and 
Committee on Energy and Commerce of the House of Represent-
atives, a report concerning the findings and recommendations 
from the review conducted under paragraph (1). 
Recommenda- 
tions. 
Assessment. 
Deadline. 
Review. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00163
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1389 
PUBLIC LAW 115–180—JUNE 5, 2018 
SEC. 202. GRANTS TO IMPROVE CARE FOR PEDIATRIC CANCER SUR-
VIVORS. 
(a) IN GENERAL.—Section 417E of the Public Health Service 
Act (42 U.S.C. 285a–11), as amended by section 101, is further 
amended by striking subsection (b) and inserting the following: 
‘‘(b) IMPROVING CARE FOR PEDIATRIC CANCER SURVIVORS.— 
‘‘(1) RESEARCH ON PEDIATRIC CANCER SURVIVORSHIP.—The 
Director of NIH, in coordination with ongoing research activi-
ties, may continue to conduct or support pediatric cancer 
survivorship research including in any of the following areas: 
‘‘(A) Outcomes of pediatric cancer survivors, including 
within minority or other medically underserved populations 
and with respect to health disparities of such outcomes. 
‘‘(B) Barriers to follow-up care for pediatric cancer sur-
vivors, including within minority or other medically under-
served populations. 
‘‘(C) The impact of relevant factors, which may include 
familial, socioeconomic, and other environmental factors, 
on treatment outcomes and survivorship. 
‘‘(D) The development of indicators used for long-term 
follow-up and analysis of the late effects of cancer treat-
ment for pediatric cancer survivors. 
‘‘(E) The identification of, as applicable— 
‘‘(i) risk factors associated with the late effects 
of cancer treatment; 
‘‘(ii) predictors of adverse neurocognitive and 
psychosocial outcomes; and 
‘‘(iii) the molecular basis of long-term complica-
tions. 
‘‘(F) The development of targeted interventions to 
reduce the burden of morbidity borne by cancer survivors 
in order to protect such cancer survivors from the late 
effects of cancer. 
‘‘(2) BALANCED
APPROACH.—In conducting or supporting 
research under paragraph (1)(A)(i) on pediatric cancer survivors 
within minority or other medically underserved populations, 
the Director of NIH shall ensure that such research addresses 
both the physical and the psychological needs of such survivors, 
as appropriate.’’. 
SEC. 203. BEST PRACTICES FOR LONG-TERM FOLLOW-UP SERVICES 
FOR PEDIATRIC CANCER SURVIVORS. 
The Secretary of Health and Human Services may facilitate 
the identification of best practices for childhood and adolescent 
cancer survivorship care, and, as appropriate, may consult with 
individuals who have expertise in late effects of disease and treat-
ment of childhood and adolescent cancers, which may include— 
(1) oncologists, which may include pediatric oncologists; 
(2) primary care providers engaged in survivorship care; 
(3) survivors of childhood and adolescent cancer; 
(4) parents of children and adolescents who have been 
diagnosed with and treated for cancer and parents of long- 
term survivors; 
(5) nurses and social workers; 
(6) mental health professionals; 
(7) allied health professionals, including physical therapists 
and occupational therapists; and 
Consultation. 
42 USC 285a–11 
note. 
Coordination. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00164
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 1390 
PUBLIC LAW 115–180—JUNE 5, 2018 
LEGISLATIVE HISTORY—S. 292: 
CONGRESSIONAL RECORD, Vol. 164 (2018): 
Mar. 22, considered and passed Senate. 
May 22, considered and passed House. 
DAILY COMPILATION OF PRESIDENTIAL DOCUMENTS (2018): 
June 5, Presidential remarks. 
(8) others, as the Secretary determines appropriate. 
SEC. 204. TECHNICAL AMENDMENT. 
(a) IN
GENERAL.—Section 3 of the Hematological Cancer 
Research Investment and Education Act of 2002 (Public Law 107– 
172; 116 Stat. 541) is amended by striking ‘‘section 419C’’ and 
inserting ‘‘section 417C’’. 
(b) EFFECTIVE DATE.—The amendment made by subsection (a) 
shall take effect as if included in section 3 of the Hematological 
Cancer Research Investment and Education Act of 2002 (Public 
Law 107–172; 116 Stat. 541). 
Approved June 5, 2018. 
42 USC 285a–10 
note. 
42 USC 285a–10. 
VerDate Sep 11 2014 
10:03 Jan 17, 2024
Jkt 079194
PO 00000
Frm 00165
Fmt 6580
Sfmt 6580
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 1\79194PT1-3.001
79194PT1-3
whamilton on LAP1Z6H6L3PROD with STATUTES